{"product_id":"mdgl-marketing-mix","title":"(MDGL) Madrigal Pharmaceuticals, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Madrigal Pharmaceuticals, Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotion tactics in a concise, structured view. This page includes a real preview\/sample of the analysis so you can assess style and content; purchase the full version to download the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRezdiffra 1 commercial product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRezdiffra (resmetirom) was FDA approved on March 14, 2024 for adults with noncirrhotic NASH and moderate to advanced fibrosis, and it became Madrigal Pharmaceuticals’ first and only marketed product. It is now the company’s core revenue driver and the shift point from clinical-stage to commercial-stage biopharma.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResmetirom oral therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResmetirom is Madrigal Pharmaceuticals, Inc.’s once-daily oral small molecule for chronic MASH treatment in specialty liver care. It is a liver-targeted selective thyroid hormone receptor-beta agonist, and its Phase 3 MAESTRO-NASH data showed 26% fibrosis improvement and 24% MASH resolution at 52 weeks. Madrigal priced Rezdiffra at about $47,400 a year at launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarch 2024 FDA approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn March 2024, the U.S. FDA granted accelerated approval for Madrigal Pharmaceuticals, Inc.'s Rezdiffra, making it the company’s first approved product. It is approved for adults with noncirrhotic MASH and moderate to advanced fibrosis, based on the 966-patient MAESTRO-NASH trial. This launch opened Madrigal’s first market revenue stream and set up its 2025 scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eF2-F3 fibrosis label\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc.’s F2-F3 fibrosis label targets adults with moderate to advanced liver scarring, so the usable pool is mainly hepatology clinics, not primary care. That fits a specialty-medicine model: the FDA-approved MASH drug Rezdiffra launched in 2024, and Madrigal reported $14.6 million Q1 2025 net product sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eF2-F3 narrows prescribing to specialists.\u003c\/li\u003e\n\u003cli\u003eFocuses on noncirrhotic MASH patients.\u003c\/li\u003e\n\u003cli\u003eSupports premium, targeted commercialization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMGL-3745 pipeline backup\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMGL-3745 gives Madrigal Pharmaceuticals, Inc. a second shot behind its 1 approved asset, resmetirom, which helps reduce single-product risk. As a backup compound, it supports long-term continuity if the lead program slows or faces setbacks. That kind of pipeline depth matters in MASH, where 1 late-stage win can drive the company.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 approved product today\u003c\/li\u003e\n\u003cli\u003eBackup lowers pipeline risk\u003c\/li\u003e\n\u003cli\u003eSupports long-term continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRezdiffra Drives Madrigal’s Early MASH Commercial Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRezdiffra is Madrigal Pharmaceuticals, Inc.'s only commercial product, an oral MASH drug for adults with noncirrhotic disease and F2-F3 fibrosis. FDA accelerated approval came on March 14, 2024, and Q1 2025 net product sales were $14.6 million. Its specialty-liver label keeps prescribing focused on hepatology clinics and supports premium pricing near $47,400 a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRezdiffra\u003c\/td\u003e\n\u003ctd\u003eOnly marketed asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e$14.6M Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P’s analysis of Madrigal Pharmaceuticals, Inc.’s product, pricing, distribution, and promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDistills Madrigal Pharmaceuticals’ 4Ps into a quick, decision-ready snapshot for faster marketing alignment and analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources used to validate Madrigal Pharmaceuticals' market, pricing, and competitive assumptions for fast verification and defensible decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. specialty pharmacy channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRezdiffra is sold through U.S. specialty pharmacies, which is standard for high-cost liver drugs because they handle prior authorization, patient onboarding, and refill tracking. This channel helps Madrigal Pharmaceuticals, Inc. keep access tight for a therapy with 2024 launch pricing of about $47,400 a year. Specialty pharmacy use also supports adherence in chronic MASH care, where treatment may run long and payer review is often required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepatology prescribers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. places Rezdiffra mainly through hepatologists and gastroenterologists, the doctors who diagnose and treat MASH and liver fibrosis. This specialist-first model matters because MASH affects about 5% of U.S. adults, or roughly 15 million people, but treatment starts in a small office network. In 2025, specialist adoption drove market access for the first FDA-approved MASH therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWest Conshohocken base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWest Conshohocken, Pennsylvania is Madrigal Pharmaceuticals, Inc.’s headquarters and U.S. control center. The company coordinates operations and commercial functions from this base, and it anchored the 2025 Rezdiffra launch, the first FDA-approved therapy for MASH. That matters because domestic execution is where access, payer coverage, and revenue growth are decided.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoche outside the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. uses Hoffmann-La Roche as its ex-U.S. development and commercialization partner, so the product can reach markets beyond Madrigal’s direct U.S. sales footprint. This setup gives Madrigal global reach without building its own overseas sales and regulatory network. In practice, Roche handles the outside-U.S. launch path, while Madrigal stays focused on the U.S. market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoche covers ex-U.S. development.\u003c\/li\u003e\n\u003cli\u003eRoche also handles ex-U.S. commercialization.\u003c\/li\u003e\n\u003cli\u003eMadrigal keeps direct U.S. sales control.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty access and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. sells Rezdiffra through specialty pharmacies, so access depends on payer approval and tight hub support. That makes \"place\" a reimbursement job too: the drug has to reach patients where liver care happens, with prior auth, benefits checks, and shipment handled fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a specialty launch, distribution is the gate. If coverage is slow, even diagnosed patients can wait, so Madrigal Pharmaceuticals, Inc. needs strong access support and pharmacy routing to keep fill rates up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRezdiffra Launches Through Specialty Channels in a 15M-Patient Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. places Rezdiffra through U.S. specialty pharmacies and specialist prescribers, mainly hepatologists and gastroenterologists, so access runs through prior auth, hub support, and refill tracking. The model fits a 2025 MASH launch in a U.S. market of about 15 million adults with the disease. Roche extends the ex-U.S. route, while Madrigal keeps direct U.S. control.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace lever\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. channel\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget doctors\u003c\/td\u003e\n\u003ctd\u003eHepatologists, gastroenterologists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx-U.S. partner\u003c\/td\u003e\n\u003ctd\u003eHoffmann-La Roche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 market base\u003c\/td\u003e\n\u003ctd\u003eAbout 15 million U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eMadrigal Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Madrigal Pharmaceuticals 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, editable document, ready for immediate use and tailored with product, price, place, and promotion insights specific to Madrigal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. centers HCP education on hepatologists and other specialists treating MASH and liver fibrosis. Its message is built around disease burden, biopsy-based diagnosis, and which adults with F2-F3 fibrosis may qualify for treatment; the MAESTRO-NASH phase 3 study enrolled 966 patients and helped support FDA approval in 2024. This keeps promotion tied to clinical need, not broad consumer outreach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMAESTRO-NASH evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. uses MAESTRO-NASH Phase III data as a core promotion tool for Rezdiffra: at week 52, NASH resolution with no worsening fibrosis was 25.9% with 80 mg and 29.9% with 100 mg, vs 9.7% on placebo. Fibrosis improvement was 24.2% and 25.9% vs 14.2%. These results, plus a low discontinuation rate, support efficacy and safety claims in the approved F2-F3 population.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congress presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. uses scientific congresses to present new data on Rezdiffra, which was the first FDA-approved treatment for noncirrhotic MASH with F2-F3 fibrosis in 2024. That presence builds trust with hepatology and gastroenterology prescribers by showing fresh trial and real-world evidence. In a specialist market with only one approved therapy in this setting, congress updates help reinforce the product’s evidence base and keep it top of mind.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient support programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. uses patient support programs to guide onboarding and reimbursement for Rezdiffra, which launched after FDA approval on March 14, 2024. In a specialty-drug launch, this matters because patients must clear prior auth and learn therapy expectations before starting treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnboarding lowers access friction.\u003c\/li\u003e\n\u003cli\u003eReimbursement support speeds start.\u003c\/li\u003e\n\u003cli\u003eEducation improves adherence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoche collaboration messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche collaboration messaging gives Madrigal Pharmaceuticals, Inc. third-party validation from a global pharma name and signals that ex-U.S. expansion is being built with a partner that has scale in more than 100 countries. Joint updates can lift confidence with physicians, payers, and investors because they show outside support for clinical and commercial execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal validation from Roche\u003c\/li\u003e\n\u003cli\u003eSupports ex-U.S. launch credibility\u003c\/li\u003e\n\u003cli\u003eBroadens investor and payer awareness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRezdiffra Gains on Strong Data, Access Support, and Hepatology Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMadrigal Pharmaceuticals, Inc. promotes Rezdiffra through hepatology-led education, using MAESTRO-NASH data and FDA approval for adults with F2-F3 MASH fibrosis. At week 52, NASH resolution was 25.9% and 29.9% vs 9.7% placebo, with fibrosis improvement at 24.2% and 25.9% vs 14.2%. It also uses congress updates, access support, and Roche messaging to build trust and speed starts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromo lever\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP education\u003c\/td\u003e\n\u003ctd\u003eFocused on hepatologists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical proof\u003c\/td\u003e\n\u003ctd\u003e966 patients in MAESTRO-NASH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess support\u003c\/td\u003e\n\u003ctd\u003eHelps prior auth and onboarding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbout $47,400 annual list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRezdiffra launched at an annual list price of about $47,400, putting Madrigal Pharmaceuticals, Inc. in the specialty-biopharmaceutical pricing tier. The price fits a branded, first-in-class therapy for the defined MASH population, where access is tied to clinical value and payer review. In 2025, this pricing still positioned Rezdiffra well below many chronic specialty drugs on an annual basis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty-drug pricing model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMadrigal prices Rezdiffra as a specialty drug, with a premium annual list price near $47,000 rather than a mass-market primary-care price. The model fits a narrow MASH with F2-F3 fibrosis pool, so value comes from clinical differentiation and the 2025 launch economics, not volume. In 2025, first-quarter net sales were $137.2 million, showing payers and specialists are still accepting the price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer authorization required\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAccess for Madrigal Pharmaceuticals, Inc. hinges on payer coverage and prior authorization, so the realized price can swing by insurer and benefit design. That makes reimbursement the main commercial lever for Rezdiffra, especially as broader formulary wins can lift volume faster than list price. In practice, the team has to keep tightening payer evidence and support to reduce delays and denials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCopay support available\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCopay support is a key part of Madrigal Pharmaceuticals, Inc.'s commercial model for Rezdiffra, which posted about $280 million in 2025 net product revenue. By lowering out-of-pocket costs for eligible patients, these programs help turn written scripts into filled scripts, which matters in a chronic disease market where persistence drives sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eReduces patient cost barriers\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports prescription fill conversion\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBacks 2025 commercial revenue growth\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo generic competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRezdiffra is Madrigal Pharmaceuticals, Inc.'s branded MASH drug, and it has no generic competitor today, so price pressure is low in the near term. Its U.S. launch in 2024 gave Madrigal early pricing power, but revenue still depends on proving clinical value and keeping payer access broad.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo generic competition\u003c\/li\u003e\n\u003cli\u003eBrand supports near-term pricing power\u003c\/li\u003e\n\u003cli\u003ePayer coverage drives sales\u003c\/li\u003e\n\u003cli\u003eClinical outcomes protect price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRezdiffra's Premium Price, Strong 2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRezdiffra is priced as a specialty MASH therapy, with an annual list price near $47,400 in 2025. That premium fits its first-in-class status and narrow F2-F3 fibrosis label. Payer review and prior authorization still shape the realized price. 2025 net product revenue reached about $280 million, showing demand at this price point.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eList price\u003c\/td\u003e\n\u003ctd\u003e~$47,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e~$280M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234600952073,"sku":"mdgl-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mdgl-marketing-mix.webp?v=1785724802","url":"https:\/\/dcfanalyst.com\/products\/mdgl-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}